AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

PYC THERAPEUTICS LTD

1.175

-0.020-1.67%

Volume:129.84K

Turnover:154.51K

Market Cap:685.33M

PE:-10.67

High:1.210

Open:1.210

Low:1.175

Close:1.195

Loading ...

Overview Company News Filings

ASX Growth Stocks With High Insider Ownership

Simply Wall St.

PYC Therapeutics Progresses Objective of Becoming Commercial-Stage Drug Developer; Shares Rise 6%

MT Newswires Live

PYC Therapeutics Ltd-Completion of Entitlement Offer

THOMSON REUTERS

PYC Raises AU$133 Million via Entitlement Offer

MT Newswires Live

Exploring 3 High Growth Tech Stocks In Australia

Simply Wall St.

ASX Growth Stocks With High Insider Ownership

Simply Wall St.

PYC Therapeutics Raises AU$9.3 Million via Retail Entitlement Offer; Shares Fall 3%

MT Newswires Live

Exploring High Growth Tech Stocks In Australia March 2025

Simply Wall St.

BRIEF-PYC Therapeutics Posts HY Revenues From Ordinary Activities A$12.7 Million

PYC Therapeutics Posts Wider Fiscal H1 Loss, Higher Revenue

MT Newswires Live

PYC Therapeutics Ltd - Hy Revenues From Ordinary Activities a$12.7 Mln

THOMSON REUTERS

PYC Therapeutics - Loss for the Half-Year Attributable a$25.6 Mln

THOMSON REUTERS

PYC Therapeutics Ltd-Despatch of Retail Offer Document

THOMSON REUTERS

PYC Therapeutics to Raise Nearly AU$146 Million via Entitlement Offer

MT Newswires Live

BRIEF-PYC Therapeutics Announces Equity Raising To Raise Up To A$146 Million

PYC Therapeutics Ltd - Offer Price of a$1.25 per Share

THOMSON REUTERS

PYC Therapeutics Ltd - Equity Raising to Raise up to a$146 Mln

THOMSON REUTERS

PYC Therapeutics - Raising via 1 for 4 Pro-Rata Accelerated Non-Renounceable Entitlement Offer

THOMSON REUTERS

BRIEF-PYC Therapeutics Seeks Trading Halt

Experts reveal 4 ASX small-cap shares to buy now

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PYC.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PYC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PYC.AU\",,,,,undefined,":{"symbol":"PYC.AU","market":"AU","secType":"STK","nameCN":"PYC THERAPEUTICS LTD","latestPrice":1.175,"timestamp":1745993520000,"preClose":1.195,"halted":0,"volume":129843,"delay":0,"nameEN":"PYC THERAPEUTICS LTD","floatShares":315767380,"shares":583260447,"eps":-0.110129,"marketStatus":"Not Yet Opened","change":-0.02,"latestTime":"04-30 16:12:00 AEST","open":1.21,"high":1.21,"low":1.175,"amount":154508,"amplitude":0.029289,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.110129,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1746057600000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":1.195,"openAndCloseTimeList":[[1745971200000,1745992800000]],"volumeRatio":0.49437482660900367,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PYC.AU\",,,,,undefined,":{"symbol":"PYC.AU","floatShares":315767380,"roa":"-58.01%","roe":"-112.79%","lyrEps":-0.095849,"volumeRatio":0.49437482660900367,"shares":583260447,"dividePrice":0,"high":1.21,"amplitude":0.029289,"preClose":1.195,"low":1.175,"week52Low":0.9,"pbRate":"12.36","psRate":"27.43","week52High":2.1,"institutionHeld":0,"latestPrice":1.175,"eps":-0.110129,"divideRate":0,"volume":129843,"delay":0,"ttmEps":-0.110129,"open":1.21,"prevYearClose":1.32,"prevWeekClose":1.115,"prevMonthClose":1.175,"prevQuarterClose":1.22,"fiveDayClose":0.99,"twentyDayClose":1.25,"sixtyDayClose":1.22},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PYC.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531998837","title":"ASX Growth Stocks With High Insider Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2531998837","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531998837?lang=en_us&edition=fundamental","pubTime":"2025-04-30 03:38","pubTimestamp":1745955480,"startTime":"0","endTime":"0","summary":"The Australian market has recently shown positive momentum, with the ASX200 closing up 0.92% at 8,070 points, driven by strong performances in sectors like Energy and Utilities. In this environment of growth and sectoral strength, identifying stocks with high insider ownership can be particularly appealing as it often suggests confidence from those who know the company best.Top 10 Growth Companies With High Insider Ownership In Australia. Click here to see the full list of 96 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.Guzman y Gomez Limited's recent sales figures show strong growth, with Q1 2025 network sales reaching A$289.5 million, up from A$234.2 million the previous year. The company has transitioned to profitability, reporting a net income of A$7.3 million for H1 2024-25 compared to a loss previously. Despite substantial insider selling over the past three months, revenue is fore","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/asx-growth-stocks-high-insider-193800414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["EIQ.AU","AAL.AU","IMA.AU","NWF.AU","TTT.AU","PYC.AU","ACR.AU","BK7007","BK7067","BK7137","XAO.AU","BK7036","GYG.AU","BK7093","BK7016","BK7508","PLT.AU","DVP.AU","FEX.AU","BK7129","XJO.AU","CYC.AU","BK7095","XKO.AU","BK7116","BK7078","BBT.AU","BK7077","BK7096"],"gpt_icon":0},{"id":"2529690917","title":"PYC Therapeutics Progresses Objective of Becoming Commercial-Stage Drug Developer; Shares Rise 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529690917","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529690917?lang=en_us&edition=fundamental","pubTime":"2025-04-24 09:39","pubTimestamp":1745458765,"startTime":"0","endTime":"0","summary":"PYC Therapeutics  said it continues to progress towards its 48-month objective of becoming a commercial-stage drug developer under its published operational roadmap, according to a Thursday Australian bourse filing.The focus for the firm now is to generate clinical proof-of-concept for each of its three clinical-stage drug candidates, per the filing.The company will start with the presentation of phase one and two data for its lead blinding eye disease drug candidate in May, the filing said.PYC Therapeutics' shares rose almost 6% in recent trading on Wednesday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","LENZ","BK4139","BK7067","SSI","PYC.AU"],"gpt_icon":0},{"id":"2528659204","title":"PYC Therapeutics Ltd-Completion of Entitlement Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2528659204","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528659204?lang=en_us&edition=fundamental","pubTime":"2025-04-17 06:35","pubTimestamp":1744842941,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nTUE4ZHSCV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","PYC.AU"],"gpt_icon":0},{"id":"2526879278","title":"PYC Raises AU$133 Million via Entitlement Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2526879278","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526879278?lang=en_us&edition=fundamental","pubTime":"2025-04-09 09:30","pubTimestamp":1744162236,"startTime":"0","endTime":"0","summary":"PYC Therapeutics  has raised AU$133 million through its ongoing entitlement offer, part of a broader AU$146 million capital raise, according to a Wednesday filing with the Australian bourse.The company expects to receive the remaining AU$13 million by April 30 after the underwriter for the outstanding balance has requested an extension citing liquidity issues, the filing said.PYC is seeking payment guarantees and a bond from the underwriter to ensure the completion of the transaction, the filing added.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PYC.AU","BK7067"],"gpt_icon":0},{"id":"2524481134","title":"Exploring 3 High Growth Tech Stocks In Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2524481134","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524481134?lang=en_us&edition=fundamental","pubTime":"2025-04-03 03:05","pubTimestamp":1743620749,"startTime":"0","endTime":"0","summary":"The Australian market has recently seen a modest uptick, with the ASX200 closing up 0.12% at 7,934 points, although sector performances have varied significantly, with Real Estate and Telecommunications leading gains while Materials and Energy lagged behind. In this environment of mixed sector performance, identifying high-growth tech stocks requires a focus on companies that demonstrate robust revenue growth and resilience in the face of fluctuating market conditions.Click here to see the full list of 50 stocks from our ASX High Growth Tech and AI Stocks screener.Underneath we present a selection of stocks filtered out by our screen.Overview: PYC Therapeutics Limited is a drug-development company focused on creating RNA-based treatments for genetic diseases, with a market cap of A$650.12 million.Operations: The company engages in the discovery and development of RNA therapeutics for genetic diseases, generating revenue of A$24.99 million from this segment.Click to explore a detailed b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exploring-3-high-growth-tech-190549374.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["WTC.AU","BK7016","XJO.AU","BK7503","QOR.AU","XAO.AU","BK7067","BK7024","XKO.AU","PYC.AU"],"gpt_icon":0},{"id":"2524060979","title":"ASX Growth Stocks With High Insider Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2524060979","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524060979?lang=en_us&edition=fundamental","pubTime":"2025-04-01 03:08","pubTimestamp":1743448092,"startTime":"0","endTime":"0","summary":"The Australian stock market recently experienced a broad downturn, with the ASX200 closing down 1.7% at 7,843 points and all sectors losing ground, particularly materials and energy. In such volatile conditions, investors often seek out growth companies with high insider ownership as these firms can offer a sense of stability and alignment of interests between management and shareholders.Top 10 Growth Companies With High Insider Ownership In Australia. Click here to see the full list of 94 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.Overview: Guzman y Gomez Limited owns, operates, and franchises quick service restaurants in Australia, Singapore, Japan, and the United States with a market cap of A$3.27 billion.Operations: The company generates revenue primarily through its quick service restaurant operations, with A$413.26 million attributed to this segment.Guzman y Gomez shows promising growth potential, with half-year sales rising to A$212.42 millio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/asx-growth-stocks-high-insider-190812718.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["FEX.AU","PYC.AU","TTT.AU","BK7096","NWF.AU","BK7129","GYG.AU","BK7078","BK7043","BK7084","FND.AU","AVA.AU","BK7007","BK7104","ACR.AU","XJO.AU","PLT.AU","BK7067","AAL.AU","BK7077","BK7116","EMR.AU","BK7508","XKO.AU","BK7093","BBT.AU","BK7137","CYC.AU","XAO.AU","BK7036","BK7158"],"gpt_icon":0},{"id":"2520668644","title":"PYC Therapeutics Raises AU$9.3 Million via Retail Entitlement Offer; Shares Fall 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2520668644","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520668644?lang=en_us&edition=fundamental","pubTime":"2025-03-18 12:00","pubTimestamp":1742270445,"startTime":"0","endTime":"0","summary":"PYC Therapeutics  raised AU$9.3 million via the retail component of its entitlement offer, bringing the total funds raised to AU$100 million, according to a Tuesday filing with the Australian bourse.On Feb. 17, the company said it is set to raise up to AU$146 million via a pro-rata accelerated non-renounceable entitlement offer on the basis of one new share for every four shares held.The balance will be raised through an underwriting facility expected before April 7, the filing said.Shares of the company fell almost 3% in recent Tuesday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PYC.AU","BK7067","LENZ","BK4139"],"gpt_icon":0},{"id":"2517886269","title":"Exploring High Growth Tech Stocks In Australia March 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2517886269","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517886269?lang=en_us&edition=fundamental","pubTime":"2025-03-05 03:05","pubTimestamp":1741115155,"startTime":"0","endTime":"0","summary":"Amidst a volatile Australian market, with key sectors like energy and utilities facing significant downturns and health care showing modest gains, investors are navigating a complex landscape influenced by global trade tensions and fluctuating commodity prices. In this environment, identifying high growth tech stocks requires careful consideration of factors such as innovation potential, adaptability to market changes, and resilience against broader economic uncertainties.Click here to see the full list of 54 stocks from our ASX High Growth Tech and AI Stocks screener.Overview: PYC Therapeutics Limited is a drug-development company focused on discovering and developing novel RNA therapeutics to treat genetic diseases in Australia, with a market cap of A$559.93 million.ASX:PYC Revenue and Expenses Breakdown as at Mar 2025. Overview: Qoria Limited is engaged in the marketing, distribution, and sale of cyber safety products and services across Australia, New Zealand, the United Kingdom, t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exploring-high-growth-tech-stocks-190555604.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["XAO.AU","BK7067","BK7016","BK7503","BK7024","QOR.AU","XKO.AU","XJO.AU","WTC.AU","PYC.AU"],"gpt_icon":0},{"id":"2514236608","title":"BRIEF-PYC Therapeutics Posts HY Revenues From Ordinary Activities A$12.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514236608","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514236608?lang=en_us&edition=fundamental","pubTime":"2025-02-27 15:27","pubTimestamp":1740641251,"startTime":"0","endTime":"0","summary":"BRIEF-PYC Therapeutics Posts HY Revenues From Ordinary Activities A$12.7 MillionFeb 27 (Reuters) - PYC Therapeutics Ltd PYC.AX:HY REVENUES FROM ORDINARY ACTIVITIES A$12.7 MILLIONLOSS FOR THE HALF-YEAR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PH1ZI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PYC.AU"],"gpt_icon":0},{"id":"2514847547","title":"PYC Therapeutics Posts Wider Fiscal H1 Loss, Higher Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2514847547","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514847547?lang=en_us&edition=fundamental","pubTime":"2025-02-27 14:43","pubTimestamp":1740638620,"startTime":"0","endTime":"0","summary":"PYC Therapeutics  reported Thursday that its loss per diluted share in the fiscal first half widened to AU$0.0549, from a loss of AU$0.04 per diluted share a year earlier.Analysts polled by Visible Alpha were expecting a diluted loss per share of AU$0.03.Revenue for the six months ended Dec. 31, 2024, was AU$12.7 million, up 39% from AU$9.1 million in the same period last year. Analysts surveyed by Visible Alpha expected AU$11.4 million in total revenue.Analysts polled by Visible Alpha expect earnings of AU$0.10 per diluted share on revenue of AU$18.7 for the full fiscal year.The firm did not pay or declare any dividends during the period.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PYC.AU","LENZ"],"gpt_icon":0},{"id":"2514846750","title":"PYC Therapeutics Ltd - Hy Revenues From Ordinary Activities a$12.7 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514846750","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514846750?lang=en_us&edition=fundamental","pubTime":"2025-02-27 13:17","pubTimestamp":1740633477,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PH1ZI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PYC.AU","BK7067"],"gpt_icon":0},{"id":"2514754846","title":"PYC Therapeutics - Loss for the Half-Year Attributable a$25.6 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514754846","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514754846?lang=en_us&edition=fundamental","pubTime":"2025-02-27 13:17","pubTimestamp":1740633477,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PH1ZI:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","PYC.AU"],"gpt_icon":0},{"id":"2513626237","title":"PYC Therapeutics Ltd-Despatch of Retail Offer Document","url":"https://stock-news.laohu8.com/highlight/detail?id=2513626237","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513626237?lang=en_us&edition=fundamental","pubTime":"2025-02-24 09:10","pubTimestamp":1740359413,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nTUE5CXD4B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","PYC.AU"],"gpt_icon":0},{"id":"2512995459","title":"PYC Therapeutics to Raise Nearly AU$146 Million via Entitlement Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2512995459","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512995459?lang=en_us&edition=fundamental","pubTime":"2025-02-17 11:44","pubTimestamp":1739763872,"startTime":"0","endTime":"0","summary":"PYC Therapeutics (ASX:PYC) is set to raise up to AU$146 million via a pro-rata accelerated non-renounceable entitlement offer on the basis of one new share for every four shares held, according to a M","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","LENZ","BK4139","PYC.AU"],"gpt_icon":0},{"id":"2512496200","title":"BRIEF-PYC Therapeutics Announces Equity Raising To Raise Up To A$146 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2512496200","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512496200?lang=en_us&edition=fundamental","pubTime":"2025-02-17 10:06","pubTimestamp":1739757997,"startTime":"0","endTime":"0","summary":"BRIEF-PYC Therapeutics Announces Equity Raising To Raise Up To A$146 MillionFeb 17  - PYC Therapeutics Ltd PYC.AX:EQUITY RAISING TO RAISE UP TO A$146 MILLIONRAISING VIA 1 FOR 4 PRO-RATA ACCELERATED NON-RENOUNCEABLE ENTITLEMENT OFFEROFFER PRICE OF A$1.25 PER SHAREFurther company coverage: PYC.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250217:nFWN3OR28C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PYC.AU","BK7067"],"gpt_icon":0},{"id":"2512968693","title":"PYC Therapeutics Ltd - Offer Price of a$1.25 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2512968693","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512968693?lang=en_us&edition=fundamental","pubTime":"2025-02-17 06:57","pubTimestamp":1739746677,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250216:nFWN3OR28C:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PYC.AU","BK7067"],"gpt_icon":0},{"id":"2512968660","title":"PYC Therapeutics Ltd - Equity Raising to Raise up to a$146 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2512968660","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512968660?lang=en_us&edition=fundamental","pubTime":"2025-02-17 06:57","pubTimestamp":1739746677,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250216:nFWN3OR28C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","PYC.AU"],"gpt_icon":0},{"id":"2512896869","title":"PYC Therapeutics - Raising via 1 for 4 Pro-Rata Accelerated Non-Renounceable Entitlement Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2512896869","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512896869?lang=en_us&edition=fundamental","pubTime":"2025-02-17 06:57","pubTimestamp":1739746677,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250216:nFWN3OR28C:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PYC.AU","BK7067"],"gpt_icon":0},{"id":"2512090950","title":"BRIEF-PYC Therapeutics Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2512090950","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512090950?lang=en_us&edition=fundamental","pubTime":"2025-02-17 06:43","pubTimestamp":1739745837,"startTime":"0","endTime":"0","summary":"BRIEF-PYC Therapeutics Seeks Trading HaltFeb 17 (Reuters) - PYC Therapeutics Ltd PYC.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT ON CAPITAL RAISINGFurther company coverage: PYC.AX ((Reuters.Briefs@thomsonreuters.com;;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250216:nFWN3OR28A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PYC.AU","BK7067"],"gpt_icon":0},{"id":"2510480131","title":"Experts reveal 4 ASX small-cap shares to buy now","url":"https://stock-news.laohu8.com/highlight/detail?id=2510480131","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510480131?lang=en_us&edition=fundamental","pubTime":"2025-02-11 09:05","pubTimestamp":1739235950,"startTime":"0","endTime":"0","summary":"Nuix Ltd  The Nuix share price is $4.74, down 0.63%. Moelis Australia has a buy rating on this ASX small-cap tech share with a price target of $6.09. Moelis responded to Nuix's 1H FY25 update, which stated it was expecting 8% to 9% growth in Annualised Contract Value  compared to the previ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/11/experts-reveal-4-asx-small-cap-shares-to-buy-now/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","NXL.AU","ACV","OPT.AU","PYC.AU","BK7508","XJO.AU","BK4139","OPT","BMN.AU","BK7083","BK7016"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":42,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PYC.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-11-15","symbol":"PYC.AU","defaultRemindTime":1731625200000,"type":"split","dateTimestamp":1731589200000,"forFactor":10,"toFactor":1,"ratio":10},{"market":"AU","date":"2024-03-18","symbol":"PYC.AU","defaultRemindTime":1710716400000,"type":"split","dateTimestamp":1710680400000,"forFactor":988235,"toFactor":1000000,"ratio":0.988235}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PYC.AU\",market:\"AU\",,,undefined,":[]}}